Compare AROC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROC | SRRK |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 4.6B |
| IPO Year | 2007 | 2018 |
| Metric | AROC | SRRK |
|---|---|---|
| Price | $35.53 | $40.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $37.67 | ★ $55.10 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-28-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 74.29 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $1,489,818,000.00 | N/A |
| Revenue This Year | $7.33 | N/A |
| Revenue Next Year | $5.44 | $449.79 |
| P/E Ratio | $18.91 | ★ N/A |
| Revenue Growth | ★ 28.70 | N/A |
| 52 Week Low | $20.12 | $22.71 |
| 52 Week High | $37.26 | $49.82 |
| Indicator | AROC | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 34.35 |
| Support Level | $23.23 | $29.32 |
| Resistance Level | $37.26 | $42.54 |
| Average True Range (ATR) | 1.15 | 2.27 |
| MACD | -0.32 | -0.67 |
| Stochastic Oscillator | 42.94 | 7.79 |
Archrock Inc is an energy infrastructure company focused on midstream natural gas compression. It is a provider of natural gas compression services, based on total compression fleet horsepower, to customers across the United States and a supplier of aftermarket services to customers that own compression equipment. The company operates through two segments: contract operations and aftermarket services. The contract operations segment includes designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining its owned fleet of natural gas compression equipment, and generates the maximum revenue. The aftermarket services segment provides operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.